Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

Autor: Steigbigel, Rt, Cooper, Da, Teppler, H, Eron, Jj, Gatell, Jm, Kumar, Pn, Rockstroh, Jk, Schechter, M, Katlama, C, Markowitz, M, Yeni, P, Loutfy, Mr, Lazzarin, A, Vullo, Vincenzo, Lennox, Jl, Clotet, B, Zhao, J, Wan, H, Rhodes, Rr, Strohmaier, Km, Barnard, Rj, Isaacs, Rd, Nguyen, By, BENCHMRK STUDY TEAMSA

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0568c65650e9d90f5d69e7bb1f8c7724
http://hdl.handle.net/11573/85920

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

Autor: Cooper, Da, Steigbigel, Rt, Gatell, Jm, Rockstroh, Jk, Katlama, C, Yeni, P, Lazzarin, A, Clotet, B, Kumar, Pn, Eron, Je, Schechter, M, Markowitz, M, Loutfy, Mr, Lennox, Jl, Zhao, J, Chen, J, Ryan, Dm, Rhodes, Rr, Killar, Ja, Gilde, Lr, Strohmaier, Vullo, Vincenzo, Meibohm, Ar, Miller, Md, Hazuda, Dj, Nessly, Ml, Dinubile, Mj, Isaacs, Rd, Teppler, H, Nguyen, By, BENCHMRK STUDY TEAMS

Background: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfd904b9414218980a2d17b85e46901
http://hdl.handle.net/11573/85775

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Autor: Steigbigel RT (AUTHOR), Cooper DA (AUTHOR), Kumar PN (AUTHOR), Eron JE (AUTHOR), Schechter M (AUTHOR), Markowitz M (AUTHOR), Loutfy MR (AUTHOR), Lennox JL (AUTHOR), Gatell JM (AUTHOR), Rockstroh JK (AUTHOR), Katlama C (AUTHOR), Yeni P (AUTHOR), Lazzarin A (AUTHOR), Clotet B (AUTHOR), Zhao J (AUTHOR), Chen J (AUTHOR), Ryan DM (AUTHOR), Rhodes RR (AUTHOR), Killar JA (AUTHOR), Gilde LR (AUTHOR)

Publikováno v: New England Journal of Medicine. 7/24/2008, Vol. 359 Issue 4, p339-354. 16p.

Reliability of pathogen control in direct potable reuse: Performance evaluation and QMRA of a full-scale 1 MGD advanced treatment train.

Autor: Pecson BM; Trussell Technologies, 1939 Harrison Street, Suite 600, Oakland, CA 94612, USA. Electronic address: brianp@trusselltech.com., Triolo SC; Trussell Technologies, 1939 Harrison Street, Suite 600, Oakland, CA 94612, USA., Olivieri S; ARC Alternatives, Inc., 222 Sutter St, Suite 600, San Francisco, CA 94108, USA., Chen EC; Trussell Technologies, 380 Stevens Avenue, Suite 308, Solana Beach, CA 92075, USA., Pisarenko AN; Trussell Technologies, 380 Stevens Avenue, Suite 308, Solana Beach, CA 92075, USA., Yang CC; Trussell Technologies, 232 North Lake Avenue, Suite 300, Pasadena, CA 91101, USA., Olivieri A; EOA, 1410 Jackson Street, Oakland, CA 94612, USA., Haas CN; Drexel University, 3141 Chestnut Street, 251 Curtis Hall, Philadelphia, PA 19104, USA., Trussell RS; Trussell Technologies, 380 Stevens Avenue, Suite 308, Solana Beach, CA 92075, USA., Trussell RR; Trussell Technologies, 232 North Lake Avenue, Suite 300, Pasadena, CA 91101, USA.

Publikováno v: Water research [Water Res] 2017 Oct 01; Vol. 122, pp. 258-268. Date of Electronic Publication: 2017 Jun 06.